A Comparison of Wharton’s Jelly and Cord Blood as a Source of Mesenchymal Stem Cells for Diabetes Cell Therapy

El-Demerdash, Rasha F; Hammad, Lamiaa N.; Kamal, Mohamed M.; Mesallamy, Hala O El

doi:10.2217/rme.15.49

Cited by 20 publications

(12 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As such, the best current practice for treating diabetes involves transplantation of the islet or pancreas [3–5], but the large numbers of patients, limited supply of donor tissue, the risk and cost of operation, and necessity for lifelong immunosuppression have limited the application of this treatment modality. β -like cells differentiated from embryonic stem cells (ES) [6], induced pluripotent stem cells (iPSCs) [7], and mesenchymal stem cells (MSC) [8] have become the most promising solution by providing a potentially inexhaustible means of generating β cells for transplantation and with low immunogenicity. Recently, Alipio et al successfully induced iPSCs to differentiate into β -like cells [9].…”

Section: Introductionmentioning

confidence: 99%

Culture of iPSCs Derived Pancreatic β-Like Cells In Vitro Using Decellularized Pancreatic Scaffolds: A Preliminary Trial

Wan

Huang

Zhou

et al. 2017

BioMed Research International

View full text Add to dashboard Cite

Diabetes mellitus is a disease which has affected 415 million patients in 2015. In an effort to replace the significant demands on transplantation and morbidity associated with transplantation, the production of β-like cells differentiated from induced pluripotent stem cells (iPSCs) was evaluated. This approach is associated with promising decellularized scaffolds with natural extracellular matrix (ECM) and ideal cubic environment that will promote cell growth in vivo. Our efforts focused on combining decellularized rat pancreatic scaffolds with mouse GFP+-iPSCs-derived pancreatic β-like cells, to evaluate whether decellularized scaffolds could facilitate the growth and function of β-like cells. β-like cells were differentiated from GFP+-iPSCs and evaluated via cultivating in the dynamic circulation perfusion device. Our results demonstrated that decellularized pancreatic scaffolds display favorable biochemical properties. Furthermore, not only could the scaffolds support the survival of β-like cells, but they also accelerated the expression of the insulin as compared to plate-based cell culture. In conclusion, these results suggest that decellularized pancreatic scaffolds could provide a suitable platform for cellular activities of β-like cells including survival and insulin secretion. This study provides preliminary support for regenerating insulin-secreting organs from the decellularized scaffolds combined with iPSCs derived β-like cells as a potential clinical application.

show abstract

Section: Introductionmentioning

confidence: 99%

Culture of iPSCs Derived Pancreatic β-Like Cells In Vitro Using Decellularized Pancreatic Scaffolds: A Preliminary Trial

Wan

Huang

Zhou

et al. 2017

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Autologous bone marrow MSCs, with the ability of homing to the target, perception of injury signals, migration to the injured site, proliferation, and differentiation, participate in tissue injury repair, achieving effective results [ 3 – 6 ]. MSCs can be obtained from mature bone marrow, fatty tissues, placenta, scalp, pancreatic tissue, endometrium, Wharton's jelly, and umbilical cord blood [ 7 – 14 ]. Under different induction conditions, MSCs can differentiate into bone, cartilage, fat, muscle, tendon, and other mesodermal cells, but also cross mesoderm differentiation, forming various ectodermal cells (e.g., neurons, gliacytes, and skin cells) and endodermal or vascular endothelial cells (e.g., liver and kidney cells) [ 15 , 16 ].…”

Section: Introductionmentioning

confidence: 99%

Advances in the Treatment of Ischemic Diseases by Mesenchymal Stem Cells

Wang

et al. 2016

Stem Cells International

View full text Add to dashboard Cite

Ischemic diseases are a group of diseases, including ischemic cerebrovascular disease, ischemic cardiomyopathy (ICM), and diabetic foot as well as other diseases which are becoming a leading cause of morbidity and mortality in the whole world. Mesenchymal stem cells (MSCs) have been used to treat a variety of ischemic diseases in animal models and clinical trials. Lots of recent publications demonstrated that MSCs therapy was safe and relieved symptoms in patients of ischemic disease. However, many factors could influence therapeutic efficacy including route of delivery, MSCs' survival and residential rate in vivo, timing of transplantation, particular microenvironment, and patient's clinical condition. In this review, the current status, therapeutic potential, and the detailed factors of MSCs-based therapeutics for ischemic cerebrovascular disease, ICM, and diabetic foot are presented and discussed. We think that MSCs transplantation would constitute an ideal option for patients with ischemic diseases.

show abstract

“…For example, MSCs from hUCB and WJ differ in their functional properties. El Demerdash et al found that WJ-derived MSCs could better differentiate into insulin producing cells in vitro and better controlled hyperglycemia in diabetic rats in vivo [8]. The differential influence of clinical variables on the cytokine and chemokine secretome and the neuronal differentiation of WJ-derived MSCs compared with hUCB-derived MSCs is unknown.…”

mentioning

confidence: 99%

Factors Influencing Yield and Neuronal Differentiation of Mesenchymal Stem Cells from Umbilical Cord Blood and Matrix

et al. 2016

View full text Add to dashboard Cite

show abstract

A Comparison of Wharton’s Jelly and Cord Blood as a Source of Mesenchymal Stem Cells for Diabetes Cell Therapy

Cited by 20 publications

References 47 publications

Culture of iPSCs Derived Pancreatic β-Like Cells In Vitro Using Decellularized Pancreatic Scaffolds: A Preliminary Trial

Culture of iPSCs Derived Pancreatic β-Like Cells In Vitro Using Decellularized Pancreatic Scaffolds: A Preliminary Trial

Advances in the Treatment of Ischemic Diseases by Mesenchymal Stem Cells

Factors Influencing Yield and Neuronal Differentiation of Mesenchymal Stem Cells from Umbilical Cord Blood and Matrix

Contact Info

Product

Resources

About